Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: Continuous or intermittent?

Respiratory Medicine

Volumn 105, Issue SUPPL. 2, 2011, Pages

  Lo, David ^a   VanDevanter, Donald R ^b   Flume, Patrick ^c   Smyth, Alan ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Aerosolized antibiotics; Continuous therapy; Cystic fibrosis; FEV1; Intermittent therapy; Randomized, controlled trials (RCTs)

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; ARIKACE; AZTREONAM LYSINE; BRAMITOB; CARBENICILLIN; CEFALORIDINE; CEFTAZIDIME; CIPROFLOXACIN; CLOXACILLIN; COLISTIN; FOSFOMYCIN; GENTAMICIN; LEVOFLOXACIN; SODIUM CHLORIDE; TOBRAMYCIN; UNCLASSIFIED DRUG;

AEROSOL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC CYSTIC FIBROSIS; CYSTIC FIBROSIS; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; INTERMETHOD COMPARISON; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SYSTEMATIC REVIEW (TOPIC); TINNITUS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MEDICATION ADHERENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 84855279786     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/S0954-6111(11)70022-1     Document Type: Article

References (46)

1. DH Andersen Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study Am J Dis Child 56 2 1938 344 399
2. PA Lewis, S Morison, JA Dodge et al. Survival estimates for adults with cystic fibrosis born in the United Kingdom between 1947 and 1967. The UK Cystic Fibrosis Survey Management Committee Thorax 54 5 1999 420 422 (Pubitemid 29199780)
3. Cystic Fibrosis Trust UK Cystic Fibrosis Registry Annual Data Report 2009 2011 Cystic Fibrosis Trust Bromley, Kent, UK
4. JA Dodge, PA Lewis, M Stanton, J Wilsher Cystic fibrosis mortality and survival in the UK: 1947-2003 Eur Respir J 29 3 2007 522 526 (Pubitemid 46372100)
5. Cystic Fibrosis Foundation US Cystic Fibrosis Foundation Annual Registry Report 2009 2010 Cystic Fibrosis Foundation Bethesda, MD
6. P Lebecque, T Leal, K Zylberberg, G Reychler, X Bossuyt, V Godding Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis J Cyst Fibros 5 4 2006 237 244 (Pubitemid 44824859)
7. TW Lee, KG Brownlee, M Denton, JM Littlewood, SP Conway Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center Pediatr Pulmonol 37 2 2004 104 110 (Pubitemid 38120979)
8. CR Hansen, T Pressler, N Hoiby Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience J Cyst Fibros 7 6 2008 523 530
9. JM Littlewood, MG Miller, AT Ghoneim, CH Ramsden Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis Lancet 1 8433 1985 865 (Pubitemid 15115129)
10. T Jensen, SS Pedersen, S Garne, C Heilmann, N Høiby, C Koch Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection J Antimicrob Chemother 19 6 1987 831 838 (Pubitemid 17092071)
11. T Schulin In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany J Antimicrob Chemother 49 2 2002 403 406 (Pubitemid 34162638)
12. BW Ramsey, MS Pepe, JM Quan et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group N Engl J Med 340 1 1999 23 30 (Pubitemid 29024680)
13. ME Hodson, CG Gallagher, JR Govan A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Eur Respir J 20 3 2002 658 664
14. AL Smith, BW Ramsey, DL Hedges et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis Pediatr Pulmonol 7 4 1989 265 271
15. BW Ramsey, HL Dorkin, JD Eisenberg et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis N Engl J Med 328 24 1993 1740 1746 (Pubitemid 23170123)
16. TD Murphy, RD Anbar, LA Lester et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease Pediatr Pulmonol 38 4 2004 314 320 (Pubitemid 39245114)
17. A Chuchalin, E Csiszér, K Gyurkovics et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study Paediatr Drugs 9 Suppl 1 2007 21 31 (Pubitemid 46879111)
18. CM Oermann, GZ Retsch-Bogart, AL Quittner et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis Pediatr Pulmonol 45 11 2010 1121 1134
19. GZ Retsch-Bogart, AL Quittner, RL Gibson et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis Chest 135 5 2009 1223 1232
20. KS McCoy, AL Quittner, CM Oermann, RL Gibson, GZ Retsch-Bogart, AB Montgomery Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis Am J Respir Crit Care Med 178 9 2008 921 928
21. WH Nikolaizik, D Vietzke, F Ratjen A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients Can Respir J 15 5 2008 259 262
22. G Ryan, M Singh, K Dwan Inhaled antibiotics for long-term therapy in cystic fibrosis Cochrane Database Syst Rev 3 2011 CD001021
23. ME Hodson, AR Penketh, JC Batten Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis Lancet 2 8256 1981 1137 1139 (Pubitemid 11029642)
24. G Nolan, P Moivor, H Levison, PC Fleming, M Corey, R Gold Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin J Pediatr 101 4 1982 626 630 (Pubitemid 12028542)
25. P Kun, LI Landau, PD Phelan Nebulized gentamicin in children and adolescents with cystic fibrosis Aust Paediatr J 20 1 1984 43 45 (Pubitemid 14123235)
26. I Nathanson, GJA Cropp, P Li, P Neter Effectiveness of aerosolized gentamicin in cystic fibrosis Cystic Fibrosis Club Abstracts 26 1985 145
27. RJ Stead, ME Hodson, JC Batten Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa Br J Dis Chest 81 3 1987 272 279 (Pubitemid 17091811)
28. Day AJ, Williams J, Mckeown C, et al. Evaluation of inhaled colomycin in children with cystic fibrosis. In: Proceedings of the 10th International Cystic Fibrosis Congress; March 5-10, 1988; Sydney, Australia. Excerpta Medica Asia Pacific Congress Series 1988;74:106. Poster R9c03.
29. IB MacLusky, R Gold, M Corey, H Levison Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa Pediatr Pulmonol 7 1 1989 42 48
30. SA McColley, B Trapnell, D Kissner et al. Fosfomycin/tobramycin for inhalation (FTI): microbiological results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa Pediatr Pulmonol 45 2010 338 Abstract 38.
31. DE Geller, PA Flume, D Staab, R Fischer, JS Loutit, DJ Conrad, Mpex204 Study Group Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa Am J Respir Crit Care Med 183 11 2011 1510 1516
32. CE Wainwright, AL Quittner, DE Geller et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa J Cyst Fibros 10 4 2011 234 242
33. G Lenoir, YG Antypkin, A Miano et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa Paediatr Drugs 9 Suppl 1 2007 11 20 (Pubitemid 46879110)
34. MJ Ledson, MJ Gallagher, M Robinson et al. A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia J Aeroso Med 15 1 2002 51 57 (Pubitemid 34327055)
35. E Kerem, J Reisman, M Corey, GJ Canny, H Levison Prediction of mortality in patients with cystic fibrosis N Engl J Med 326 18 1992 1187 1191
36. AL Quittner, A Buu, MA Messer, AC Modi, M Watrous Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis Chest 128 4 2005 2347 2354 (Pubitemid 41507578)
37. IM Hoffmann, BK Rubin, SS Iskandar, MS Schechter, SK Nagaraj, MM Bitzan Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy Pediatr Pulmonol 34 5 2002 375 377 (Pubitemid 35192792)
38. D Dulon, H Hiel, C Aurousseau, JP Erre, JM Aran Pharmacokinetics of gentamicin in the sensory hair cells of the organ of Corti: rapid uptake and long term persistence C R Acad Sci III 316 7 1993 682 687 (Pubitemid 23288742)
39. JL Burns, JM Van Dalfsen, RM Shawar et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis J Infect Dis 179 5 1999 1190 1196 (Pubitemid 29196500)
40. BA Briesacher, AL Quittner, L Saiman, P Sacco, H Fouayzi, LM Quittell Adherence with tobramycin inhaled solution and health care utilization BMC Pulm Med 11 2011 5
41. J LeLorier, S Perreault, H Birnbaum, P Greenberg, O Sheehy Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis Clin Ther 22 1 2000 140 151 (Pubitemid 30091431)
42. DE Geller, MW Konstan, J Smith, SB Noonberg, C Conrad Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety Pediatr Pulmonol 42 4 2007 307 313 (Pubitemid 46608898)
43. JJ LiPuma Microbiological and immunological considerations with aerosolized drug delivery Chest 120 3 Suppl 2001 118S 123S
44. AL Smith, SB Fiel, N Mayer-Hamblett, B Ramsey, JL Burns Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis Chest 123 5 2003 1495 1502 (Pubitemid 36549768)
45. SD Aaron, K Vandemheen, W Ferris et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, doubleblind, controlled clinical trial Lancet 366 9484 2005 463 471 (Pubitemid 41111694)
46. DR VanDevanter, M Ballmann, PA Flume Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis Respir Med 105 Suppl 2 2011 S18 S23